Form 4: Cencora CEO Exercises Options, Sells Shares Under Pre-Arranged Plan

Cencora Inc.'s President and CEO, Robert P. Mauch, exercised stock options and subsequently sold a portion of his common stock holdings pursuant to a Rule 10b5-1 trading plan.

Summary

• Robert P. Mauch, President & CEO and Director of Cencora, Inc. (COR), engaged in an insider transaction on July 18, 2025.
• Mauch acquired 3,225 shares of Common Stock by exercising non-qualified stock options at an exercise price of $86.09 per share.
• Concurrently, Mauch disposed of 4,968 shares of Common Stock at a price of $294.11 per share.
• The sale of shares was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Mauch on November 15, 2024.
• Following these transactions, Mauch beneficially owns 42,351 shares of Common Stock.
• Mauch also holds 25,802 non-qualified stock options (right to buy) with an exercise price of $86.09, which expire on November 13, 2026.
• These options were exercisable in four equal installments on November 13, 2020, November 13, 2021, November 13, 2022, and November 13, 2023.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan, which is a common practice for executive compensation and personal financial management. It does not indicate any significant positive or negative operational or financial news for the company.

Positives

• The sale price of $294.11 per share is significantly higher than the exercise price of $86.09, indicating a profitable transaction for the insider.
• The transaction was conducted under a Rule 10b5-1 trading plan, which suggests a pre-scheduled, non-discretionary sale, often viewed as a routine part of executive compensation and personal financial management rather than a reaction to new company-specific information.

Negatives

• While routine, insider sales, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, though this is typically mitigated by the pre-arranged nature of the plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing represents a routine insider transaction, common across all industries for executives managing their equity compensation. The use of a Rule 10b5-1 trading plan is a standard practice to allow insiders to sell shares without being accused of trading on material non-public information.

Comparison to Industry Standards

• The exercise of stock options and subsequent sale of shares is a standard component of executive compensation packages across various industries, including the pharmaceutical and healthcare distribution sector where Cencora operates.
• The adoption of a Rule 10b5-1 trading plan is a widely accepted corporate governance practice for insiders to manage their equity holdings in a pre-planned, compliant manner, aligning with best practices observed in comparable large-cap companies.

Stakeholder Impact

• Shareholders: The transaction represents a routine insider sale, which is generally not expected to have a significant direct impact on the company's operational performance or long-term strategic direction. The volume of shares sold is relatively small in the context of a large publicly traded company.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CEO exercised stock options and sold a portion of the resulting shares under a pre-arranged 10b5-1 trading plan. Such transactions are common for executive compensation and personal financial management and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment strategy based solely on this report. Therefore, a 'hold' recommendation is appropriate as this filing does not provide new information that would alter the investment thesis.

Keywords

Cencora, COR, Insider Trading, Form 4, Stock Option, Equity, Executive Compensation, Robert P. Mauch, Rule 10b5-1